Research Press Release

Targeting new anti-cancer drugs

Nature Communications

February 22, 2012

Directly targeting a specific part of the β-catenin protein could provide a new leads in the development of drugs for cancers in which this protein is mutated reports a study in Nature Communications this week. Mutations in β-catenin are important in a range of cancers, including colorectal cancer. Mariann Bienz and co-workers identified a chemical compound that inhibits the interaction of β-catenin with its cofactor BCL9. The compound is found to rely upon a specific part of β-catenin, suggesting that specifically targeting this part of the protein may provide a new strategy to develop direct inhibitors of oncogenic β-catenin. These preliminary findings may aid the development of new anti-cancer drugs.

DOI:10.1038/ncomms1680 | Original article

Research highlights

PrivacyMark System